Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citalopram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.89 |
| ▸ | HTR2C | P28335 | 2/20 | 0.89 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.89 |
| ▸ | HRH1 | P35367 | 2/20 | 0.89 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.89 |
| ▸ | DRD3 | P35462 | 2/20 | 0.89 |
| ▸ | HTR2B | P41595 | 2/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.89 |
| ▸ | NPC1 | O15118 | 1/20 | 0.89 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.89 |
| ▸ | HTR1A | P08908 | 1/20 | 0.89 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.89 |
| ▸ | DRD1 | P21728 | 1/20 | 0.89 |
| ▸ | ACHE | P22303 | 1/20 | 0.89 |
| ▸ | HRH2 | P25021 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Escitalopram SCHEMBL30223023 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL35123 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL29604018 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL27936829 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL28369040 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL28980945 | 0.97 | SLC6A4 (0.94) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL28631467 | 0.97 | SLC6A4 (0.94) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL3287650 | 0.94 | SLC6A4 (0.90) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| (R)-Citalopram SCHEMBL13235283 | 0.94 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL946 | 0.94 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661849-A1 | AN IMMEDIATE-RELEASE ORAL PHARMACEUTICAL FORM OF ESCITALOPRAM OR RACEMATE THEREOF WITH INCREASED API CONTENT | Kinast, Lasse (DE) | 2025-12-17 | — | — | EP | claimed |
| WO-2024165628-A1 | AN IMMEDIATE-RELEASE ORAL PHARMACEUTICAL FORM OF ESCITALOPRAM OR RACEMATE THEREOF WITH INCREASED API CONTENT | KINAST LASSE (DE) | 2024-08-15 | — | — | WO | claimed |
| US-7365216-B2 | Process for the production of citalopram | MATRIX LABORATORIES LIMITED (IN) | 2008-04-29 | — | — | US | claimed |
| CN-1267427-C | Process for production of citalopram | MATRIX LAB LTD (IN) | 2006-08-02 | — | — | CN | claimed |
| US-20040259939-A1 | Process for the production of citalopram | MATRIX LABORATORIES LIMITED (IN) | 2004-12-23 | — | — | US | claimed |
| EP-1478635-A1 | PROCESS FOR THE PRODUCTION OF CITALOPRAM | Matrix Laboratories Limited (IN) | 2004-11-24 | — | — | EP | claimed |
| WO-2004085416-A1 | NOVEL CRYSTALLINE FORMS OF (S)-CITALOPRAM OXALATE | HETERO DRUGS LIMITED (IN) | 2004-10-07 | — | — | WO | claimed |
| CN-1509279-A | Process for production of citalopram | ʵ | 2004-06-30 | — | — | CN | claimed |
| WO-2003072565-A1 | PROCESS FOR THE PRODUCTION OF CITALOPRAM | MATRIX LABORATORIES LIMITED (DE) | 2003-09-04 | — | — | WO | claimed |
| EP-4661849-A1 | AN IMMEDIATE-RELEASE ORAL PHARMACEUTICAL FORM OF ESCITALOPRAM OR RACEMATE THEREOF WITH INCREASED API CONTENT | Kinast, Lasse (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4661849-A1 | AN IMMEDIATE-RELEASE ORAL PHARMACEUTICAL FORM OF ESCITALOPRAM OR RACEMATE THEREOF WITH INCREASED API CONTENT | Kinast, Lasse (DE) | 2025-12-17 | — | — | EP | disclosed |
| US-12419879-B2 | Combination therapy for the treatment of pancreatic cancer | GENENTECH, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| CN-120583942-A | Immediate release oral pharmaceutical dosage form of escitalopram or racemate thereof with increased API content | 拉塞·凯那司特 | 2025-09-02 | — | — | CN | disclosed |
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| WO-2001051478-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001043525-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2001-06-21 | — | — | WO | disclosed |
| EP-1105382-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. Lundbeck A/S (DK) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000023431-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000013648-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000011926-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419879-B2 | Combination therapy for the treatment of pancreatic cancer | JAK2, STAT3, STAT6 | SLC6A4 3789/4885MAPK1 187/4885LMNA 4636/4885 |
| US-20040259939-A1 | Process for the production of citalopram | HTR5A, COMT, MAOB | SLC6A4 23/4885MAPK1 3680/4885LMNA 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.